Karampas Grigorios, Koulouraki Sevasti, Daikos George L, Nanou Christina, Aravantinos Leon, Eleftheriades Makarios, Metallinou Dimitra, Christopoulos Panagiotis
Second Department of Obstetrics and Gynaecology, Aretaieio University Hospital, National and Kapodistrian University of Athens, 115 28 Athens, Greece.
Mitera Hospital, 6, Erythrou Stavrou Str., 151 23 Athens, Greece.
J Clin Med. 2024 Apr 20;13(8):2400. doi: 10.3390/jcm13082400.
Visceral leishmaniasis (VL), often referred to as kala-azar, is quite rare in developed countries during pregnancy. Only few studies have evaluated its impact on perinatal outcome. It is caused primarily by or and presents with a wide spectrum of clinical manifestations from cutaneous ulcers to multisystem disease. Differential diagnosis is challenging as symptoms and signs are insidious, mimicking other diseases. Misdiagnosis can result in severe adverse perinatal outcomes, even maternal/neonatal death. Early treatment with liposomal amphotericin-B (LAmB) is currently the first choice with adequate effectiveness. We report a rare case of VL in a twin pregnancy with onset at the second trimester, presenting with periodic fever with rigors, right flank pain, and gradual dysregulation of all three cell lines. The positive rK39 enzyme-linked immunosorbent assay test confirmed the diagnosis. Treatment with LAmB resulted in clinical improvement within 48 h and in the delivery of two late-preterm healthy neonates with no symptoms or signs of vertical transmission. The one-year follow-up, of the mother and the neonates, was negative for recurrence. To our knowledge, this is the first reported case of VL in a twin pregnancy, and consequently treatment and perinatal outcome are of great importance.
Mediterr J Hematol Infect Dis. 2022-7-1
Trans R Soc Trop Med Hyg. 2001-4
Cureus. 2023-1-12
BMC Infect Dis. 2023-12-18
Pharmacotherapy. 2023-5
Front Cell Infect Microbiol. 2021
Front Cell Infect Microbiol. 2020
Biosens Bioelectron. 2021-1-1